Oryzon Genomics to Share Updates on Corporate Progress
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a leading clinical-stage biopharmaceutical company dedicated to epigenetic therapies for critical medical needs, is set to present its latest corporate updates at several major international events. These important gatherings scheduled for September will showcase the company’s research achievements and innovative treatment strategies.
Upcoming Conferences Featuring Oryzon
Oryzon's participation in significant conferences demonstrates its dedication to enhancing its clinical portfolio and boosting its visibility in the global biotech arena. One notable event is the German Fall Conference 2024, which will take place on September 2-3 at the historic Le Meridien Hotel in Frankfurt. During this conference, Oryzon will provide updates on corporate developments on September 3 at 13:45 CET and will also hold one-on-one meetings with potential partners and investors.
European College of Neuropsychopharmacology Congress
Another key event on Oryzon's agenda is the 37th European College of Neuropsychopharmacology (ECNP) congress, occurring from September 21-24. At this congress, Oryzon will share important findings from its Phase IIb PORTICO trial, which investigates the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). Dr. Michael Ropacki, Oryzon’s Chief Medical Officer for CNS, will present the results in an oral communication titled "Final Results: PORTICO, a double-blind, randomized placebo-controlled, adaptive phase IIb trial to assess vafidemstat’s efficacy in treating borderline personality disorder," during the ECNP New Medication Symposium on September 23.
Sachs Annual Biotech in Europe Forum
Furthering its engagement with the international biotech community, Oryzon has been invited to participate in the 24th Sachs Annual Biotech in Europe Forum 2024, scheduled for September 25-26. Oryzon executives will take part in a keynote plenary panel titled "Neurological Disorders Panel: Rapid Advances with New Targets & Modalities," set for September 25 at 17:10 CET, showcasing the company’s leadership in tackling neurological disorders.
Understanding Oryzon's Clinical Pipeline
Established in 2000 in Spain, Oryzon Genomics is recognized as a pioneer in epigenetic therapies, focusing on personalized medicine to address challenges in Central Nervous System (CNS) disorders and oncology. The company has a strong pipeline that includes two primary LSD1 inhibitors: vafidemstat for CNS applications and iadademstat for oncology, both currently in multiple Phase II clinical trials. Additionally, Oryzon is advancing ORY-4001, which targets HDAC-6, a key factor in conditions such as Charcot-Marie-Tooth disease (CMT) and Amyotrophic Lateral Sclerosis (ALS).
Innovative Clinical Approaches
Oryzon employs state-of-the-art technologies for biomarker identification and validation across various malignancies and neurological diseases. The company’s commitment to developing effective therapies is highlighted by its clinical trials for both vafidemstat and iadademstat, which have demonstrated promising safety and efficacy in challenging patient populations.
Contacting Oryzon Genomics
Oryzon Genomics is based in Barcelona, Spain, and operates with a dedicated team focused on pharmaceutical development. For any inquiries, please reach out to the following contacts:
**IR, US:** Ashley R. Robinson, LifeSci Advisors, LLC - +1 617 430 7577 - arr@lifesciadvisors.com
**IR & Media, Europe:** Sandya von der Weid, LifeSci Advisors, LLC - +41 78 680 05 38 - svonderweid@lifesciadvisors.com
**IR in Spain:** Patricia Cobo, Atrevia - +34 91 564 07 25 | +34 673 33 97 65 | pcobo@atrevia.com
**Chief Business Officer:** Emili Torrell - +34 93 515 1313 - etorrell@oryzon.com
Frequently Asked Questions
What is Oryzon Genomics known for?
Oryzon Genomics specializes in epigenetic therapies aimed at treating CNS disorders and cancer, with a focus on addressing unmet medical needs.
What events will Oryzon attend in September?
Oryzon will participate in the German Fall Conference, the ECNP Congress, and the Sachs Annual Biotech in Europe Forum, where they will provide updates on their clinical progress.
What is vafidemstat?
Vafidemstat (ORY-2001) is an oral LSD1 inhibitor designed to target cognitive impairment and neuroinflammation in CNS disorders.
Where can I find more information about Oryzon?
For more details about Oryzon Genomics, you can visit their official website.
How can I contact Oryzon for investor relations?
Interested parties can reach out to Oryzon's investor relations team using the provided contacts for inquiries related to investment or media.
